 Home > Active Ingredient News > Antitumor Therapy > PD-L1 single-resistant Bavencio, FDA approved for maintenance treatment for patients with late or metastatic urethra skin cancer

PD-L1 single-resistant Bavencio, FDA approved for maintenance treatment for patients with late or metastatic urethra skin cancer

 Last Update: 2020-07-14
 Source: Internet
 Author: User

Tags

terlipressin fda approval

metastatic endometrial cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Merck and Pfizer announced that the U.SFood and Drugadministration(
FDA) has expanded its application range for the maintenance of local late or metastatic urinary tract cancer (UC) patients with first-line platinum-containing chemotherapyPhoto Source:This approval is based on the results of the PHASE III JAVELIN Bladder 100 study, which showed a significant increase of 7.1 months in primary overall survival (OS) as a first-line maintenance treatment (BSC) compared to the use of best support treatment (BSC) alone, 14.3 months and 21.4 months, respectivelyThe statistically significant improvement in OS resulted in a 31% reduction in the risk of death for the entire patient population"As the firstimmunotherapy that showed a statistically significant improvement in overall survival rates in the first-line treatment of locally advanced or metastatic urethra skin cancer, the FDA approved avelumab as one of the most important advances in the treatment of the disease in 30 years," said Petros Grivas, lead researcher on the JAVELIN Bladder 100 trialplatinum-based chemotherapy is currently the first-line treatment standard for patients with advanced urinary skin cancer with high response rates, but most patients progress earlier than five years of treatment, with only 5% of patients having a pre-metastasis life expectancy of more than five years

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.